However, in a study employing CD34 + BMSCs intravitreal injections (with 3.4 × 106 cells in a 0.1 ml suspension), no improvement in visual function was observed in 6 patients affected by AMD, even if no complications occurred [79, 82]. This evidence concerns the gene CD34 and age-related macular degeneration.